Taisho Pharmaceuticals Philippines Adopts ESGpedia to Strengthen Sustainability Reporting and ESG Performance

Operating in the Philippines, Taisho Pharmaceuticals manufactures, imports, distributes, and manages pharmaceuticals and energy drinks, leveraging the country’s strategic position as one of Southeast Asia’s largest pharmaceutical markets.

Taisho Pharmaceutical’s Sustainability Journey

Growing Sustainability Requirements in the Philippines

The pharmaceutical and healthcare industries contribute approximately 5% of global carbon emissions, placing increasing pressure on companies to act.

With the Philippines facing rising expectations from local and ASEAN regulators, customers, and investors, alongside the shift toward mandatory sustainability reporting for listed companies, non-listed entities like Taisho Pharmaceuticals are facing trickle-down implications and growing momentum to embark on transparent and impactful sustainability initiatives.

Taisho Pharmaceuticals’ ESG Goals: Enhancing Sustainability Capabilities with Digital Sustainability Reporting & Supplier Engagement

To gain clarity on its ESG performance, Taisho Pharmaceuticals first pursued an EcoVadis assessment in 2022 for an independent benchmark and required a structured, scalable method to advance on their sustainability reporting journey.

Taisho Pharmaceuticals has since leveraged the ESGpedia digital platform and expert support to generate trusted, GRI-aligned Sustainability Reports, gain real-time visibility into Greenhouse Gas (GHG) emissions, and embark on active supplier engagement, positioning the company to secure globally recognised ratings such as the EcoVadis Gold medal.

Generation of GRI-aligned Sustainability Report

With pre-aligned GRI questionnaires which provided ‘clear guidance without requiring extensive in-house technical expertise’, the ESGpedia platform enabled Taisho Pharmaceuticals to efficiently generate their GRI-aligned FY2023 and FY2024 Sustainability Reports.

This transformation enabled Taisho Pharmaceuticals to move away from manual processes, gain real-time visibility into ESG performance, and credibly communicate their sustainability impact to stakeholders.

Actionable, Real-time Insights into GHG Emissions

Comprehensive, centralised dashboards and analytics further empowered Taisho Pharmaceuticals to monitor and track GHG emissions, complemented by actionable insights on emissions hotspots in their value chain to facilitate better-informed decarbonisation strategies.

Enhanced Supply Chain ESG Management

A tailored Supplier Engagement questionnaire using ESGpedia’s Supply Chain ESG Module streamlined supplier collaboration and data collection through a centralised digital system.

In addition to advancing sustainable procurement decisions for Taisho Pharmaceuticals, this supplier engagement lays the groundwork for the company to embark on Scope 3 emissions tracking and reporting in the future.

Why ESGpedia?

Taisho Pharmaceuticals recognised ESGpedia as a reliable and outcome-driven ESG solution partner that aligned with its needs and available resources, following an engagement with the Global Compact Network Philippines.  

On top of providing a scalable digital platform, ESGpedia offered expert support and proactive guidance from its team of experienced sustainability and data experts.

Driving measurable ESG impact and tangible business outcomes through digital transformation

The adoption of ESGpedia’s platform has strengthened Taisho Pharmaceuticals’ position as an ESG leader in the Philippine pharmaceutical industry, enabling them to achieve:

• Strengthened sustainability reporting and climate resilience capabilities to better navigate growing pressures in the Philippines and ASEAN markets.
• EcoVadis Gold Medal recognition, enhancing brand reputation and investor appeal.
• Enhanced sustainable supply chain management and visibility into value chain emissions.
• Heightened business competitiveness through data-backed ESG progress and credentials.

Read the full case study article here.